US2019322669A1PendingUtilityA1

Pyrazolopyrimidine compounds

Assignee: UNIV HEALTH NETWORKPriority: Nov 16, 2012Filed: Dec 19, 2018Published: Oct 24, 2019
Est. expiryNov 16, 2032(~6.3 yrs left)· nominal 20-yr term from priority
A61P 43/00A61P 35/00C07D 487/04C07D 519/00
69
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present teachings provide a compound represented by the following structural formula: (Formula (I)); or a pharmaceutically acceptable salt thereof. Also described are pharmaceutical compositions and methods of use thereof.

Claims

exact text as granted — not AI-modified
1 - 7 . (canceled) 
     
     
         8 . A method for treating cancer, the method comprising administering to a subject in need thereof an effective amount of a compound represented by the following structural formula: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, wherein: 
         R 1  is —NH—CH 2 —Cy, 
         Cy is C 3 -C 4  cycloalkyl optionally substituted with one or two groups selected from alkyl and hydroxyl; 
         R 2  is —O-pyridinyl; —NH—(C 2 -C 6 )hydroxyalkyl optionally substituted with cyclopropyl or isopropyl; or —NH—(C 3 -C 6 )cycloalkyl optionally substituted with hydroxyl or (C 1 -C 2 )hydroxylalkyl; 
         R 4  is selected from hydrogen, halogen, and (C 1 -C 3 )alkyl; and 
         R d  is cyclopropyl. 
       
     
     
         9 . The method of  claim 8 , wherein the cancer is pancreatic cancer, prostate cancer, lung cancer, melanoma, breast cancer, colon cancer, or ovarian cancer.

Join the waitlist — get patent alerts

Track US2019322669A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.